Drug Type Small molecule drug |
Synonyms Sovaprevir (USAN), ACH-0141625, ACH-1625 |
Target |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC43H53N5O8S |
InChIKeyMHFMTUBUVQZIRE-WINRQGAFSA-N |
CAS Registry1001667-23-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10166 | Sovaprevir | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 2 | - | 01 Apr 2013 | |
Hepatitis C, Chronic | Phase 2 | US | 01 Sep 2010 | |
Hepatitis C, Chronic | Phase 2 | BE | 01 Sep 2010 |
Phase 2 | 30 | Placebo | gdbpaodzqx(jqkvjdzmud) = apozopfcir eusixubqte (itdjvlrpvt, vutaskjjcw - qwvttbqenj) View more | - | 04 Feb 2015 |